Caregivers' perspectives on lecanemab use for Alzheimer's disease: A national survey in China.

ABSTRACT:

Introduction

Caregivers' decisions significantly influence Alzheimer's disease progression, yet research on the benefits of disease-modifying therapy (DMT) from their perspective is limited.

Methods

This cross-sectional survey included 345 informal caregivers of lecanemab-treated patients. We collected online questionnaires from 37 tertiary hospitals across 31 provinces/autonomous regions/municipalities in China (2024/06/24 ∼ 2024/12/24).

Results

Approximately 94.5% of the caregivers opined that the burden of care did not intensify (including remaining constant or being alleviated) subsequent to the administration of lecanemab, among which 25.8% of the caregivers stated that the burden of care was mitigated. Those caregivers with a higher annual family income (≥¥400,0

SUBMITTER: Liu S 

PROVIDER: S-EPMC12450581 | biostudies-literature | 2025 Sep

REPOSITORIES: biostudies-literature